MM

BEHAVIORAL3 trials

Sponsors

Institut für Pharmakologie und Präventive Medizin, NYU Langone Health, University of Campania Luigi Vanvitelli

Conditions

Aortic Valve StenosisHemorrhoidsOpioid Use Disorder (OUD)

Phase 2

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Active, not recruitingNCT04464980

NYU Langone HealthOpioid Use Disorder (OUD)

Start: 2021-06-08End: 2027-01-31Updated: 2025-12-15

Unknown Phase

Validation of the TASQ in Patients Undergoing SAVR or TF-TAVI

CompletedNCT03186339

Institut für Pharmakologie und Präventive MedizinAortic Valve Stenosis

Start: 2017-09-08End: 2020-01-13Updated: 2022-05-18

Minimal Invasive Laser Hemorrhoidoplasty vs Conventional Excisional Hemorrhoidectomy in II-III Grade Hemorrhoidal Disease

CompletedNCT04944407

University of Campania Luigi VanvitelliHemorrhoids

Start: 2017-01-01End: 2020-12-31Updated: 2021-06-29

Related Papers

Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).

2025-01-201 citations

Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper

BMJ Open2024-11-012 citations

Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.

2024-04-231 citations

Quality of life after transcatheter or surgical aortic valve replacement using the Toronto Aortic Stenosis Quality of Life Questionnaire

Open Heart2021-11-0113 citations

Trial protocol for the validation of the <i>‘</i>Toronto Aortic Stenosis Quality of Life (TASQ) Questionnaire’ in patients undergoing surgical aortic valve replacement (SAVR) or transfemoral (TF) transcatheter aortic valve implantation (TAVI): the TASQ registry

Open Heart2019-05-0121 citations